Molecular mechanisms and targeted interventions for embolic risk in cardiac myxoma: from molecular heterogeneity to clinical translation - Takeaways - MDSpire

Molecular mechanisms and targeted interventions for embolic risk in cardiac myxoma: from molecular heterogeneity to clinical translation

  • By

  • Shichao Guo

  • Zhiyuan Wang

  • Yingying Guo

  • Youwei Zhao

  • July 7, 2026

  • 0 min

Share

  • 1

    Cardiac myxoma is the most common primary cardiac tumor, with embolic complications occurring in 10%-25% of patients.

  • 2

    Recent advances in single-cell and spatial transcriptomics have revealed the active biological processes driving embolism in cardiac myxoma.

  • 3

    A specific PLAT-high tumor subpopulation and dysregulated phosphodiesterase signaling contribute to the embolic risk in cardiac myxoma.

  • 4

    The tumor microenvironment, particularly M2 macrophages, plays a significant role in promoting tumor survival and enhancing embolic potential.

  • 5

    Integrating molecular insights with clinical models may improve embolism prediction and inform targeted therapies for cardiac myxoma.

Original Source(s)

Molecular mechanisms and targeted interventions for embolic risk in cardiac myxoma: from molecular heterogeneity to clinical translation

  • by Shichao Guo, Zhiyuan Wang, Yingying Guo, Youwei Zhao

  • July 7, 2026

Related Content

Exploring the Narratives of Patients With Cancer Using Large Language Models: Topic Modeling and Social Network Analysis

Integrative radiomics and habitat imaging models for predicting PD-L1 expression in non-small cell lung cancer

Prostate Cancer Screening—Where We’ve Been, Where We Are, and What Comes Next